AstraZeneca plans to spend $50 bln to expand US manufacturing and research by 2030.

AstraZeneca plans to spend $50 bln to expand US manufacturing and research by 2030.

AstraZeneca has unveiled plans to invest $50 billion in the United States by 2030, aiming to expand its manufacturing and research and development capabilities. This significant investment will support the company's ambition to reach $80 billion in total revenue by 2030, with 50% of that revenue expected to come from the U.S. market [1].

The cornerstone of this investment is a proposed multi-billion dollar drug substance manufacturing center in the Commonwealth of Virginia. This facility will produce drug substances for AstraZeneca's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products [1]. The new state-of-the-art center will leverage AI, automation, and data analytics to optimize production and is expected to be the company's largest single manufacturing investment to date [2].

In addition to the Virginia facility, AstraZeneca plans to expand its R&D capabilities in Maryland and Massachusetts. The company will establish a state-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts, and expand its R&D facility in Gaithersburg, Maryland [1]. Advanced manufacturing facilities for cell therapy will be constructed in Rockville, Maryland, and Tarzana, California. Continuous and specialty manufacturing will be expanded in Mount Vernon, Indiana, and Coppell, Texas, respectively [2].

The investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country, contributing to the growth of cutting-edge medicines for patients both domestically and globally [1]. This investment aligns with the U.S. government's focus on ending the country's reliance on foreign supply of key pharmaceutical products and strengthening the domestic supply chain [3].

AstraZeneca's CEO, Pascal Soriot, stated, "Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030" [1].

The U.S. is AstraZeneca's largest market and home to 19 R&D, manufacturing, and commercial sites. The company employs more than 18,000 people and supports 92,000 jobs overall across the United States [1]. In 2024, AstraZeneca contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy.

References:
[1] https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html
[2] https://www.marketscreener.com/news/astrazeneca-to-invest-usd50-billion-in-us-facilities-by-2030-ce7c5cdcda80f627
[3] https://www.gurufocus.com/news/2991992/astrazeneca-azn-to-invest-50-billion-in-us-by-2030-azn-stock-news